GB2576914A - Antigen-binding molecules comprising unpaired variable domains produced in mammals - Google Patents

Antigen-binding molecules comprising unpaired variable domains produced in mammals Download PDF

Info

Publication number
GB2576914A
GB2576914A GB1814529.2A GB201814529A GB2576914A GB 2576914 A GB2576914 A GB 2576914A GB 201814529 A GB201814529 A GB 201814529A GB 2576914 A GB2576914 A GB 2576914A
Authority
GB
United Kingdom
Prior art keywords
domain
human
antibody
unpaired
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1814529.2A
Other languages
English (en)
Other versions
GB201814529D0 (en
Inventor
Dowd Stephen
Lindsay Wood Andrew
Lee E-Chiang
Linton Craig Hannah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Priority to GB1814529.2A priority Critical patent/GB2576914A/en
Publication of GB201814529D0 publication Critical patent/GB201814529D0/en
Priority to PCT/EP2019/073767 priority patent/WO2020049128A1/en
Priority to JP2021512749A priority patent/JP2021536478A/ja
Priority to US17/274,103 priority patent/US12473378B2/en
Priority to EP19765467.6A priority patent/EP3846620A1/en
Publication of GB2576914A publication Critical patent/GB2576914A/en
Priority to JP2024168973A priority patent/JP2024177226A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB1814529.2A 2018-09-06 2018-09-06 Antigen-binding molecules comprising unpaired variable domains produced in mammals Withdrawn GB2576914A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GB1814529.2A GB2576914A (en) 2018-09-06 2018-09-06 Antigen-binding molecules comprising unpaired variable domains produced in mammals
PCT/EP2019/073767 WO2020049128A1 (en) 2018-09-06 2019-09-05 Antigen-binding molecules comprising unpaired variable domains
JP2021512749A JP2021536478A (ja) 2018-09-06 2019-09-05 対合していない可変ドメインを含む抗原結合分子
US17/274,103 US12473378B2 (en) 2018-09-06 2019-09-05 Antigen-binding molecules comprising unpaired variable domains
EP19765467.6A EP3846620A1 (en) 2018-09-06 2019-09-05 Antigen-binding molecules comprising unpaired variable domains
JP2024168973A JP2024177226A (ja) 2018-09-06 2024-09-27 対合していない可変ドメインを含む抗原結合分子

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1814529.2A GB2576914A (en) 2018-09-06 2018-09-06 Antigen-binding molecules comprising unpaired variable domains produced in mammals

Publications (2)

Publication Number Publication Date
GB201814529D0 GB201814529D0 (en) 2018-10-24
GB2576914A true GB2576914A (en) 2020-03-11

Family

ID=63921217

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1814529.2A Withdrawn GB2576914A (en) 2018-09-06 2018-09-06 Antigen-binding molecules comprising unpaired variable domains produced in mammals

Country Status (5)

Country Link
US (1) US12473378B2 (https=)
EP (1) EP3846620A1 (https=)
JP (2) JP2021536478A (https=)
GB (1) GB2576914A (https=)
WO (1) WO2020049128A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
EP4512243A1 (en) 2023-08-21 2025-02-26 Kymab Limited Binding molecules
CN117587070B (zh) * 2024-01-19 2024-04-30 北京仁源欣生生物科技有限公司 一种经遗传修饰的非人哺乳动物的制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022477A2 (en) * 2005-08-17 2007-02-22 Multicell Immunotherapeutics, Inc. Methods and compositions to generate and control the effector profile of t cells
WO2014143185A1 (en) * 2012-05-24 2014-09-18 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2018038469A1 (ko) * 2016-08-20 2018-03-01 (주)아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP2319301B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
KR101151957B1 (ko) 2004-07-22 2012-06-01 로저 킹돈 크레이그 결합 분자
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
GB0601513D0 (en) * 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding molecules 3
MX2008010561A (es) * 2006-02-15 2009-03-02 Imclone Systems Inc Anticuerpos funcionales.
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
US20090148905A1 (en) 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
EP2669298A3 (en) 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
DK3622815T3 (da) * 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
ES2724975T3 (es) 2009-12-10 2019-09-18 Regeneron Pharma Ratones que producen anticuerpos de cadena pesada
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2658869B1 (en) * 2010-12-30 2019-06-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigen binding formats for use in therapeutic treatments or diagnostic assays
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
US9631191B2 (en) * 2012-12-04 2017-04-25 Alexey Gennadievich Zdanovsky System for production of antibodies and their derivatives
WO2014102100A1 (en) * 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Heterologous intron within an immunoglobulin domain
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
IL322083A (en) 2016-08-24 2025-09-01 Teneobio Inc Non-human transgenic animals that produce modified heavy chain antibodies only
EP3625250B1 (en) 2017-07-21 2021-04-14 Trianni, Inc. Single chain vh and heavy chain antibodies
EP3746470A1 (en) * 2018-01-31 2020-12-09 F. Hoffmann-La Roche AG Stabilized immunoglobulin domains
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022477A2 (en) * 2005-08-17 2007-02-22 Multicell Immunotherapeutics, Inc. Methods and compositions to generate and control the effector profile of t cells
WO2014143185A1 (en) * 2012-05-24 2014-09-18 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2018038469A1 (ko) * 2016-08-20 2018-03-01 (주)아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법

Also Published As

Publication number Publication date
JP2024177226A (ja) 2024-12-19
JP2021536478A (ja) 2021-12-27
GB201814529D0 (en) 2018-10-24
US20210395397A1 (en) 2021-12-23
EP3846620A1 (en) 2021-07-14
WO2020049128A1 (en) 2020-03-12
US12473378B2 (en) 2025-11-18

Similar Documents

Publication Publication Date Title
US12077595B2 (en) Single domain antibodies that bind to CD137
RU2762835C2 (ru) Трансгенные животные, отличные от человека, продуцирующие модифицированные антитела, содержащие только тяжелые цепи
RU2569157C2 (ru) Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
AU2005263994B2 (en) Binding molecules
BR112020023508A2 (pt) Anticorpos anti-cd3 e usos dos mesmos
JP2021519610A (ja) 多価抗体
JP2023106392A (ja) Ｃｄ３抗原結合性断片及びその使用
TW202132351A (zh) 抗cd47/抗pd-l1抗體及其應用
WO2008122886A2 (en) Transgenic non-human mammal with homodimeric vh binding complex
KR20090114350A (ko) 형질전환 동물에서의 중쇄만의 항체의 생성
KR20250027562A (ko) Dll3 및 cd3에 특이적으로 결합하는 항원 결합 분자 및 이의 의약적 용도
KR20220080381A (ko) Gpc3에 특이적인 항체 및 이의 용도
KR20260051069A (ko) 안정화된 cd3 항원 결합제 및 그 사용 방법
AU2018302343B2 (en) Single chain vh and heavy chain antibodies
GB2576914A (en) Antigen-binding molecules comprising unpaired variable domains produced in mammals
TW202241509A (zh) Anti-pd-1抗體及其用途
TW202246333A (zh) 特異性結合ｂｃｍａ和ｃｄ３的抗原結合分子及其醫藥用途
KR20250046283A (ko) Gucy2c 및 cd3에 특이적으로 결합하는 항원 결합 분자 및 이의 의약적 용도
KR20220116490A (ko) 공통 리더 서열을 갖는 bcr 트랜스제닉 마우스
JP2022532388A (ja) 改善されたラムダ抗体
WO2024094151A1 (en) Multi-specific antibody and medical use thereof
JP6996825B2 (ja) 修飾ＣκおよびＣＨ１ドメイン
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
EP4512243A1 (en) Binding molecules
WO2025131077A1 (zh) 抗cd3多特异性抗体及用途

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)